Metex Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for purine and pyrimidine synthesis. This hampers DNA, RNA and protein production, reducing the proliferation of rapidly dividing cells, including immune cells and malignant cells, thereby providing immunosuppressive and anticancer effects.

The dose of Metex Pen is individualized by the treating physician based on the patient’s condition, weight, renal function and response to therapy. The prescriber determines the exact amount, frequency and duration of treatment, and patients should follow the written prescription without alteration.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal harm and is contraindicated in pregnancy. It is also excreted in breast milk and may affect the infant. Women of child‑bearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To request Metex Pen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate, the active ingredient in Metex Pen, is an antimetabolite that directly interferes with folate metabolism, whereas many other immunosuppressants (e.g., biologic agents) target specific cytokines or cell surface receptors. Methotrexate is often less expensive, can be administered subcutaneously, and has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but its safety monitoring requirements differ.

Metex Pen should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking. If a short period at room temperature is unavoidable, follow the manufacturer’s guidance on maximum exposure time.

Metex Pen is a pre‑filled, single‑use pen designed for subcutaneous injection. The patient or healthcare professional selects the prescribed dose, removes the needle guard, and injects the medication into the subcutaneous tissue of the thigh, abdomen or upper arm, rotating sites with each injection to reduce local irritation.

The most serious risks include severe liver toxicity, bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis or interstitial pneumonitis, acute renal failure, and life‑threatening infections. Patients should be monitored regularly for liver enzymes, blood counts and renal function, and any signs of respiratory distress or infection require immediate medical attention.

Metex Pen is contraindicated in pregnant or breastfeeding women, patients with known hypersensitivity to methotrexate, those with severe hepatic or renal impairment, and individuals with active, uncontrolled infections. It should also be avoided in patients receiving live vaccines or in combination with other drugs that markedly increase methotrexate toxicity without close supervision.